advantages including reducing treatment costs decreasing factor dosages reducing risk of an immune reaction such as anaphylaxis and also decreases the risk of antibody formation specific for the blood coagulation factors furthermore inhibitors of blood coagulation factors are not produced thus therapy is simplified preferred therapeutic compositions of the present invention include between from about 0 1 nm to about 10 nm of activated blood coagulation factors typically recombinant factor viia rfviia and selected phospholipid vesicles as discussed previously particular phospholipid vesicles comprise anionic phospholipids at about physiological ph preferably phosphatidylcholine and phosphatidylserine pcps the preferred weight to volume w v of pcps is comprised between from about 50 w v to about 75 w v phosphatidylcholine and between from about 10 w v to about 25 w v phosphatidylserine more preferably the weight to volume w v of pcps is comprised between from about 75 w v to about 90 w v phosphatidylcholine and between from about 25 w v to about 50 w v phosphatidylserine most preferably the weight to volume w v of pcps is comprised between from about 50 w v to about 90 w v phosphatidylcholine and between from about 10 w v to about 50 w v phosphatidylserine preferred use of the composition involves administration of a coagulation effective amount usually between from about 10 to about 1000 fold less the amount of the same factor used in conventional therapies although it will be appreciated that precise dosage and treatment regimens will vary according to recognized parameters including but not limited to patient health age sex etc a preferred unit dose of the pcps is between from about 1 arbitrary unit to about 300 arbitrary units per kg body weight more preferably the unit dose of the pcps is between from about 300.